AI led internal programs and an aptamer based diagnostics pipeline.
Internal therapeutic programs and an aptamer based diagnostics pipeline, driven by the same discovery engine.
Discovery AI is already running real programs.
Research and diagnostics is where our platform proves itself on our own programs. Using Discovery AI and our own laboratories, we run internal therapeutic and diagnostic discovery, both to build value directly and to demonstrate the engine that our customers and partners can use.
Internal programs.
We run our own discovery programs using Discovery AI, targeting conditions where RNA and DNA approaches offer genuine advantage over existing standards of care. Programs focus on rapid candidate generation, biomarker work and clinical trial readiness, spanning areas such as neurological disease, infectious disease, cardiometabolic disease and oncology.
Therapeutic discovery pipeline.
Discovery AI is actively designing antisense oligonucleotide and RNA silencing candidates across several high need therapeutic areas, designed from the outset for manufacturability and biomarker and endpoint readiness. Programs are described in general terms while they progress through discovery and validation.
Aptamer diagnostics pipeline.
We use Discovery AI to design aptamer based point of care diagnostic tests built on molecular signatures. Aptamers are stable, synthetic and highly specific, which makes them well suited to rapid, point of care formats. Our pipeline spans a range of high need conditions, with programs advancing through design and validation.
Proof the engine works
Our first AI discovered candidate was designed by Discovery AI and has entered laboratory validation, the first candidate to complete the full discovery to laboratory workflow. It is proof that the platform can take a program from a target to a real, testable molecule.
Ready to work with an integrated life sciences company?
Talk to our team about your program, from candidate design to trial ready material.